Navigation Links
GenVec Announces Update of Safety and Efficacy Data from Pivotal,Phase II/III PACT Study of TNFerade at ASCO

Ferade(TM), is currently in a pivotal Phase II/III study (PACT) in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and seasonal and pandemic flu. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Preliminary clinical trial data cannot be considered predictive of final trial outcome. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Excha
'"/>




Page: 1 2 3 4

Related medicine technology :

1. GenVec Presents Research on New Ad35 Adenovector at ARVO
2. GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:11/21/2014)... Depomed, Inc. (NASDAQ: DEPO ) today announced that it ... Healthcare Conference in New York City . ... 8:00 am EST (5:00 am PST) on Tuesday December 2, 2014.  ... via the Investor Relations page of the Depomed website at ... 30 days on the company,s website. About Depomed ...
(Date:11/21/2014)... Texas , Nov. 21, 2014  Lexicon Pharmaceuticals, ... pricing of its previously announced underwritten public offering of ... an effective shelf registration statement. The offering will consist ... offering price of $1.005 per share.  Lexicon has also ... to 7,462,687 additional shares of common stock.  All of ...
(Date:11/18/2014)... 18, 2014  Sanguine Biosciences – a biotechnology ... study recruitment – will use its proprietary mobile ... Pfizer Inc. find and recruit people diagnosed with ... members to participate in voluntary research, which will ... and hopefully aid in informing the development of ...
Breaking Medicine Technology:Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Lexicon Announces Pricing Of Common Stock Offering 2Lexicon Announces Pricing Of Common Stock Offering 3Sanguine's Mobile Application to Assist Recruitment for Pfizer Inc. Chronic Pain Research 2
... 23, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) is pleased ... in the reduction of more than $620,000 in debt for ... and new consulting agreement will result in a reduction of ... posted its financial statements for period ended June 30, 2011. ...
... Aug. 23, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ... ), a leading pharmaceutical company specializing in the ... proprietary pharmaceuticals in China, today announced that Biqi, ... inspection. The EU-GMP certificate was issued ...
Cached Medicine Technology:Solos Endoscopy to Reduce Debt by Over $620,000 2Simcere's Branded Generic Formulation Biqi Passes EU-GMP Inspection 2
(Date:11/21/2014)... Recently, TideStore.com, a leading online store offering ... special offer TideStore Thanksgiving Sales . According to ... now provided with big discounts. The special offer is ... an extra 10% discount with this coupon code: thanks. ... have opportunities to win free gifts. TideStore.com has done ...
(Date:11/21/2014)... November 21, 2014 TopConsumerReviews.com recently ... an industry leader in the relief of ... significant feelings of sadness and depression each year ... pharmaceutical choices. Often, prescription drugs can produce worse ... drugs are expensive and require regular follow-up visits ...
(Date:11/21/2014)... November 21, 2014 RankingBySEO has announced ... the online reputation of lawyers, and the company has ... announced the service for lawyers since it receives queries ... reputation in big numbers. So far, the company has ... law firms in different parts of the world, and ...
(Date:11/21/2014)... November 21, 2014 First Choice ... 7am today. The new facility is located at 225 ... , “We are pleased to join the Friendswood ... emergency medical care here,” said Dr. Siddiqi, Facility Medical ... , To celebrate the opening, First Choice Emergency Room ...
(Date:11/21/2014)... November 21, 2014 M3 Global Research ... healthcare professional panel, today announced two important leadership changes to ... DasGupta as President of Market Research, Americas and the promotion ... , Ms. DasGupta joined M3 in 2011 and ... recently Head of Sales. Roni has over 17 years ...
Breaking Medicine News(10 mins):Health News:Thanksgiving Sales from TideStore.com 2Health News:Depression Relief Product Receives Top 5-Star Rating from TopConsumerReviews.com 2Health News:RankingBySEO Announces Lawyer Reputation Management Service 2Health News:First Choice Emergency Room Opens New Facility in Friendswood, Texas 2Health News:M3 Global Research Announces Leadership Team Promotions in US and EU 2
... Leading Urology Annual MeetingSUNNYVALE, Calif., April 23 Accuray ... in the field of radiosurgery, announced today that more ... date worldwide using the CyberKnife(R) Robotic Radiosurgery System. In ... approximately 400 prostate cancer patients were treated. The company ...
... say , , THURSDAY, April 23 (HealthDay News) -- The type ... how many calories you burn during your workout, new research ... that do not cause a spike in blood sugar -- ... more fat during a post-breakfast workout than did those who ...
... Operational Expense For The Quarter Was $4.9 Million ... (Nasdaq: PCYC ) today reported financial ... 31, 2009. The net loss for the third ... $0.25 per share, compared to a net loss ...
... Enterprises, Inc. (OTC Bulletin Board: GNPH) (the "Company"),a ... the People,s,Republic of China, today announced that it ... , The Company received ... of Florida that the Certificate of Amendment to ...
... million represents a decrease of 6.3% reported (1.5% constant currency)- ... decrease of 10.8% from the prior year period, and $0.95 ... - Reaffirms full-year sales and adjusted EPS guidanceWARSAW, Ind., April ... SWX: ZMH) today reported financial results for the quarter ended ...
... 23 OTC Perspectives - a new division within ... Inc. - has announced the finalists for the 2009 ... named as finalists are Aleve, Benadryl, Claritin, Mucinex, MiraLAX, ... National Advertising Awards will be announced June 4, 2009, ...
Cached Medicine News:Health News:CyberKnife Radiosurgery Used to Treat More Than 3,000 Prostate Cancer Patients Worldwide 2Health News:CyberKnife Radiosurgery Used to Treat More Than 3,000 Prostate Cancer Patients Worldwide 3Health News:CyberKnife Radiosurgery Used to Treat More Than 3,000 Prostate Cancer Patients Worldwide 4Health News:A Pre-Workout Meal to Help You Burn Fat 2Health News:A Pre-Workout Meal to Help You Burn Fat 3Health News:Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results 2Health News:Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results 3Health News:Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results 4Health News:Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results 5Health News:Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results 6Health News:Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name 2Health News:Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name 3Health News:Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results 2Health News:Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results 3Health News:Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results 4Health News:Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results 5Health News:Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results 6Health News:Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results 7Health News:Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results 8Health News:Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results 9Health News:Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results 10Health News:Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results 11Health News:Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results 12Health News:Zimmer Holdings, Inc. Reports First Quarter 2009 Financial Results 13Health News:J&J, Schering-Plough, Novartis, Bayer vie for Top Honors at the Premier OTC / Healthcare Ad Awards 2
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
... Since 1991 Intersurgical ... breathing filters, heat and ... oxygen therapy products, hand-held ... range of accessories and ...
... Ulti-Mist™ HME product line has the right ... to adults and from intubated patients to ... humidification for both anesthesia and critical care ... provide maximum protection for patients and staff ...
Medicine Products: